



2018 Discovery Fast Track: Australian Challenge

Helpful tips for principal investigators


About the submission process

- Useful information about the 2018 Discovery Fast Track Australian Challenge terms and conditions will be available at www.gsk.com/discoveryfasttrack.
- Entries into the 2018 Discovery Fast Track Australian Challenge are made via submission of a **one-page non-confidential** proposal. Submissions will open 19 March 2018 and close 27 April 2018.
- Submissions will not progress to the GSK review cycle until your Technology Transfer Office (TTO) has reviewed the proposal to verify compliance with the rules of the Challenge. During the online submission process, you will be asked to provide an email address for the relevant TTO.
- Ideally, the TTO should have reviewed the proposal prior to formal submission to the Challenge. If this step is done, then TTO approval via the GSK portal will be expedited and your proposal will advance to the review stage more quickly.
- The rules of the Challenge should be reviewed and followed carefully to avoid disqualification of a submission. Visit www.gsk.com/discoveryfasttrack for details.

Points to consider when entering the 2018 Discovery Fast Track Australian Challenge

- If you are unsure whether the submission contains confidential information, please contact your TTO for assistance. At this initial stage, GSK does not want to accept confidential information that must be protected or that may preclude patent protection later.
- If your proposal is selected to become a finalist, an expanded confidential proposal (~5 pages) will be required, which will be subject to an appropriate confidentiality agreement.
- Your submission(s) and any associated materials required to execute the proposed screen must be free from any third-party obligations that would prevent GSK from obtaining rights under the Challenge rules and agreements. If you have questions about what obligations are associated with your proposed concept, please contact your TTO as soon as possible for assistance.
- GSK will require appropriate rights to proceed with the proposed research (e.g. High Throughput Screening). Therefore, submitting investigators will need to verify that the materials required to perform this research are not encumbered by agreements, obligations or restrictions that prevent their use for commercial purposes.
- If co-investigators helped to develop the concept outlined in the Challenge proposal, they must agree to the submission in accordance with the Challenge rules.

Work flow for 2018 Discovery Fast Track Australian Challenge



Once the screen is complete, four research conclusions are possible:



The DPAC team is comprised of leading GSK scientists with a broad range of backgrounds across numerous therapeutic areas and drug target classes. The collaboration between the DPAC team and academic institutions brings together the insight and creativity of the academic world with the drug discovery expertise of GSK to establish truly integrated partnerships that can translate innovative research into medicines that benefit patients.

Visit www.gsk.com/discoveryfasttrack